Adaptive Biotechnologies Corp (ADPT) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Adaptive Biotechnologies’s revenue went from $38M in fiscal 2017 to $277M in fiscal 2025, growth of about 28.0% a year.
Net income in fiscal 2025 was -$59M, a net margin of -21.5%; the best year in this period was 2017 with -$43M.
Over the twelve months to September 30, 2026, revenue was $298M and net income -$71M.
Free cash flow was -$49M in fiscal 2025 and positive in 1 of the 9 years shown.
The diluted share count rose 1144% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $298M | $277M | $179M | $170M | $185M | $154M | $98M | $85M | $56M | $38M |
| Gross profit | $221M | $206M | $107M | $95M | $127M | $105M | $76M | $63M | $36M | $23M |
| Operating income | -$48M | -$57M | -$163M | -$227M | -$200M | -$209M | -$153M | -$78M | -$50M | -$44M |
| Net income | -$71M | -$59M | -$159M | -$225M | -$200M | -$207M | -$146M | -$69M | -$46M | -$43M |
| EPS (diluted) | $-0.45 | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | $-1.01 | $-3.67 | $-3.50 |
| R&D | $83M | $94M | $103M | $122M | $142M | $142M | $116M | $71M | $39M | $32M |
| Revenue growth | — | +54.8% | +5.1% | −8.1% | +20.1% | +56.9% | +15.7% | +52.8% | +44.8% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4M | -$46M | -$95M | -$156M | -$184M | -$193M | -$150M | $205M | -$32M | -$35M |
| Capital spending | -$5M | -$3M | -$4M | -$11M | -$16M | -$62M | -$19M | -$11M | -$6M | -$2M |
| Free cash flow | -$9M | -$49M | -$99M | -$167M | -$200M | -$254M | -$168M | $194M | -$39M | -$37M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $46M | $51M | $54M | $63M | $55M | $43M | $25M | $13M | $11M | $7M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $227M | $222M | $346M | $498M | $353M | $688M | $577M | $165M | — |
| Debt | — | $210M | $223M | $229M | $233M | $112M | $108M | — | — | — |
| Equity | — | $219M | $203M | $308M | $464M | $604M | $743M | $571M | -$258M | -$225M |
| Total assets | — | $513M | $539M | $661M | $857M | $923M | $1.1B | $912M | $333M | — |
| Shares (diluted) | 187M | 152M | 147M | 144M | 143M | 140M | 131M | 69M | 13M | 12M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.2% | 74.2% | 59.7% | 55.6% | 68.8% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating margin | -16.2% | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.2% | -89.4% | -115.7% |
| Net margin | -23.7% | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.7% | -83.4% | -111.4% |
| FCF margin | -3.0% | -17.7% | -55.2% | -98.1% | -108.1% | -164.9% | -171.3% | 228.3% | -69.3% | -97.0% |
| ROIC | — | -13.3% | -38.2% | -42.2% | -22.7% | -23.1% | -14.2% | -10.8% | — | — |
| ROE | — | -27.2% | -78.7% | -73.0% | -43.1% | -34.3% | -19.7% | -12.0% | 18.0% | 19.1% |
Frequently asked questions
What is Adaptive Biotechnologies’s annual revenue?
$277M in fiscal 2025 and $298M over the twelve months to September 30, 2026.
How much profit does Adaptive Biotechnologies make?
Net income was -$59M in fiscal 2025 (net margin -21.5%).
Is Adaptive Biotechnologies’s revenue growing?
Yes: revenue rose 54.8% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.